HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (Version 3.0, dated 10/31/19) DAIDS Document ID: 20725
Give PrEP a Shot!
You may be eligible for a research study that features:
-free and confidential HIV/STI testing
-free counseling and referrals
Learn more about HPTN 083, a research study comparing the effectiveness of injections and oral tablets to prevent HIV.
-A man (assigned male sex at birth) or a transgender woman who has sex with men
-Age 18 or older
-Able to attend study visits where HPTN 083 is being conducted
|Recruitment Contact Name:||Positive Choices Unit|
|Contact Phone:||443-310-6738 (call or text)|
Location of Study Visits:
Study will provide compensation: Yes